Skip to content
‹ Back to IndustriesHealthcare

Open Enrollment Season: What Employers and Employees Need to Know Before it Ends

Employers and employees are in the thick of open enrollment season, and the end date is coming to close. For the ACA marketplace, for example, open enrollment ends on January 15, 2023. Overall, companies are going to have to make important decisions about what health insurance they offer to employees, and employees will need to…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Free workspace

Turn your Healthcare expertise into content.

Record interviews, organize footage, and write with AI in a free MarketScale workspace. Qualifying companies also get one professional video edit a month. No credit card.

Start free

Employers and employees are in the thick of open enrollment season, and the end date is coming to close. For the ACA marketplace, for example, open enrollment ends on January 15, 2023. Overall, companies are going to have to make important decisions about what health insurance they offer to employees, and employees will need to wade through the options to figure out which plans best suit their needs, whether those are ACA-offered, employer-offered, or otherwise.

Nick Love, a Benefit Strategist at Brinson Benefits breaks down what beneficiaries need to know about this year’s open enrollment seasons, along with some other tips, misconceptions and more for employers and employees alike.

Nick’s Thoughts:

“We typically see employers just not take open enrollment seriously. Unfortunately, that has a pretty big impact for employees in their households. So, I would encourage employers to take open enrollment, seriously, and for employees as well. Take your time evaluating all the options that you have at your disposal.

Compare what your spouse or significant other has through their employer and make the best decision for you and your family based on the things being offered to both you and your spouse. One thing to keep in mind is whatever you decide at open enrollment remains in effect for a full year unless you have a qualifying life event, which, usually includes things like getting married, getting divorced, having a child, those sort of things.

And so, when that happens, you have a very specific timeframe to notify HR. And so that, that timeframe is 30 days. Make sure you do that within that range so that you can make those mid-year. I would say education’s a big deal. Understanding what deductibles are, what co-insurance means what it’s gonna cost when you go to the doctor, those sort of things.

Some of the things that I think we’re gonna see more of in 2023 are folks gravitating towards HSA plans and more, taking on more of a responsibility in terms of what it’s gonna cost them when they go to the doctor and how they’re going to use that information to make the best decision as to where to go, when to go.

I think we’re gonna continue to see telemedicine have a big impact on people’s decisions and really leaning on the ability to speak to a provider via a telephone or through your computer and not having to physically go to a doctor’s office.”

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0. No credit card. Company confirmation required.

More Healthcare Insights

Medicare will pay up to $137.53 per case in 2027 for BriefCase‑Triage

Medicare will pay up to $137.53 per case in 2027 for BriefCase‑Triage

Radiology Business reported Medicare will pay a maximum of $137.53 per case in 2027 for BriefCase-Triage. Holland & Knight said hospitals will be eligible for NTAP reimbursement for use of Aidoc’s CARE Body CT Multi-Triage beginning Oct. 1, 2026, with supplemental payments continuing for three years.

  • 01Radiology Business reported Medicare will pay a maximum of $137.53 per case in 2027 for BriefCase-Triage.
  • 02Holland & Knight said CMS approved an NTAP designation for Aidoc’s CARE Body CT Multi-Triage, with hospitals eligible for NTAP reimbursement beginning Oct. 1, 2026, with supplemental payments continuing for three years.

Sep 23, 2026

Blair Health raises CAD $4.24M to expand its LLM-guided specialty care workflows

Blair Health raises CAD $4.24M to expand its LLM-guided specialty care workflows

Blair Health raised CAD $4.24 million in a pre-seed round, according to Fierce Healthcare. It plans to expand protocol-driven virtual specialty care across Canada and the U.S.

  • 01Blair Health raised CAD $4.24 million in pre-seed funding.
  • 02Qualified Health positions its AI platform around safety and governance, including clinician oversight, auditability and traceability, according to Fierce Healthcare.

Sep 23, 2026

NICE recommends Enhertu for HER2-low advanced breast cancer in England

NICE recommends Enhertu for HER2-low advanced breast cancer in England

American Pharmaceutical Review reported that NICE has recommended Enhertu for routine NHS use in people with HER2-low advanced breast cancer, following a commercial agreement and updates to NICE’s methods under the U.K.-U.S. Pharmaceutical Pricing Agreement.

  • 01NICE tied the reversal to 2026 changes: higher cost-effectiveness thresholds that took effect in April and a new quality-of-life assessment method published Aug. 27, 2026.
  • 02Access planning still varies by nation: Fierce Pharma reported Wales requires funding within 60 days of final guidance, while Scotland and Northern Ireland follow separate processes.

Sep 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512